Clinical Trials Logo

ALK Gene Rearrangement Positive clinical trials

View clinical trials related to ALK Gene Rearrangement Positive.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04146571 Available - Clinical trials for Non-Small Cell Lung Cancer

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).